No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
505 |
4. Check minimum number of eventsNone |
505 |
5. Include endpointsNone |
505 |
6. Filter based on genotype QC (FinnGen only) |
453 |
Control definitions (FinnGen only)
- Control exclude
- H7_OCUMUSCLE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other specified and unspecified strabismus
based on the number of shared cases.
Similar with more cases:
- Other strabismus
- Strabismus
- Disorders of ocular muscles, binocular movement, accommodation and refraction
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4547 | 2406 | 2136 |
| Only index persons | 3496 | 1882 | 1614 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.07 | 0.06 |
| Only index persons | 0.07 | 0.07 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 9.45 | 11.12 | 7.46 |
| Only index persons | 16.21 | 20.13 | 11.64 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 453 | 294 | 159 |
| Unadjusted period prevalence (%) | 0.09 | 0.10 | 0.07 |
| Median age at first event (years) | 44.84 | 44.41 | 45.63 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 475
- Matched controls
- 4750
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H50.9
ICD-10 Finland
Strabismus, unspecified
4551.2
252.6
221
*
H50.8
ICD-10 Finland
Other specified strabismus
+∞
228.1
200
*
H53.2
ICD-10 Finland
Diplopia
25.3
123.7
91
44
H50.0
ICD-10 Finland
Convergent concomitant strabismus
843.8
75.4
72
*
H50.2
ICD-10 Finland
Vertical strabismus
411.5
72.8
71
*
37309
ICD-8 Finland
Strabismus, Unspecified
+∞
65.1
61
*
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
+∞
64.0
60
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
6.6
58.5
110
208
H50.1
ICD-10 Finland
Divergent concomitant strabismus
+∞
53.1
50
*
H50.31
ICD-10 Finland
Intermittent exotropia
+∞
52.0
49
*
CEC00
NOMESCO Finland
Recession of extraocular muscle
+∞
49.9
47
*
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
10.3
47.5
56
61
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.3
46.8
167
535
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
94.4
39.5
43
5
H50.30
ICD-10 Finland
Intermittent esotropy
+∞
32.7
31
*
H50.52
ICD-10 Finland
Exophoria
50.5
27.8
33
7
H03BB01
ATC
carbimazole; oral
6.4
26.6
46
78
37300
ICD-8 Finland
Strabismus, Concomitans convergens
+∞
25.2
24
*
CEC60
NOMESCO Finland
Transposition of extraocular muscle with adjustable suture
+∞
25.2
24
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
7.0
24.7
39
60
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
7.6
24.5
36
51
CEW99
NOMESCO Finland
Other operation on extraocular muscle
+∞
24.2
23
*
CA1BG
NOMESCO Finland
Eye and orbita MRI examination with high intensity magnet
68.6
23.1
26
*
H062, E050,
ICD-10 Finland
+∞
21.0
20
*
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
+∞
21.0
20
*
H50.51
ICD-10 Finland
Esophoria
115.1
20.7
22
*
H52.1
ICD-10 Finland
Myopia
7.3
19.3
29
42
H50.6
ICD-10 Finland
Mechanical strabismus
+∞
18.9
18
*
XCK00
NOMESCO Finland
Perimetry
4.6
18.5
46
108
H49.1
ICD-10 Finland
Fourth [trochlear] nerve palsy
+∞
17.8
17
*
H53.1
ICD-10 Finland
Subjective visual disturbances
3.6
15.6
55
167
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.2
14.4
63
219
BAA60
NOMESCO Finland
Total thyroidectomy
5.6
14.4
28
53
H53.0
ICD-10 Finland
Amblyopia ex anopsia
23.1
14.3
20
9
CEC90
NOMESCO Finland
Total transposition of extraocular muscle or muscles
+∞
13.6
13
*
E89.01
ICD-10 Finland
Postsurgical hypothyroidism
6.3
13.5
23
38
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.2
13.3
166
949
3503
FHL
Single muscle retroposition
+∞
12.6
12
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
25.1
12.5
17
7
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.0
12.5
202
1267
H52.0
ICD-10 Finland
Hypermetropia
10.4
12.1
23
23
Z3231
NOMESCO Finland
Registered nurse
2.1
11.5
150
864
37301
ICD-8 Finland
Strabismus, Concomitans divergens
+∞
11.5
11
*
F95
ICPC
Strabismus
122.9
11.5
12
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
3.7
11.4
37
106
ZXE10
NOMESCO Finland
More than one and less than three hours
2.0
11.2
177
1091
ZXA00
NOMESCO Finland
Right side
2.1
10.8
126
693
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.7
10.8
65
268
H52.3
ICD-10 Finland
Anisometropia and aniseikonia
28.8
10.8
14
5
H06.2
ICD-10 Finland
Dysthyroid exophthalmos
61.4
10.7
12
*
H02.4
ICD-10 Finland
Ptosis of eyelid
5.2
10.6
22
44
N03AX14
ATC
levetiracetam; systemic
5.0
10.6
23
48
CAC30
NOMESCO Finland
Decompression of orbit to sinuses
+∞
10.5
10
*
H02AB06
ATC
prednisolone; systemic
1.9
9.9
224
1541
AA1AD
NOMESCO Finland
CT of head and brain
2.0
9.5
128
739
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
5.3
9.4
19
37
H51.1
ICD-10 Finland
Convergence insufficiency and excess
+∞
9.4
9
*
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
+∞
9.4
9
*
CEC30
NOMESCO Finland
Resection of extraocular muscle
+∞
9.4
9
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
9.1
133
789
ZXD20
NOMESCO Finland
Day surgery
2.4
9.0
69
319
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
3.3
8.8
34
109
WX402
NOMESCO Finland
General anaesthesia
2.0
8.6
121
707
CAC44
NOMESCO Finland
Combined decompression of orbit
91.6
8.4
9
*
37303
ICD-8 Finland
Strabismus, Heterophoria (exophoria, esophroria, hypophoria)
+∞
8.4
8
*
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
+∞
8.4
8
*
H03AA01
ATC
levothyroxine sodium; systemic
1.9
8.3
118
691
ZXD10
NOMESCO Finland
Scheduled procedure
1.8
8.3
176
1170
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
14.8
8.2
13
9
ZX120
NOMESCO Finland
Intravenous
2.5
8.2
53
226
XCD10
NOMESCO Finland
Electrophysiological examination of eye
4.9
8.2
18
38
H05.2
ICD-10 Finland
Exophthalmic conditions
34.0
8.1
10
*
L04AX01
ATC
azathioprine; systemic
3.7
8.0
25
70
ZXA05
NOMESCO Finland
Left side
1.9
7.8
107
617
WX002
NOMESCO Finland
Sedation and analgesia
2.0
7.5
88
481
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.2
7.4
67
332
CA1BM
NOMESCO Finland
Eye and orbita MRI examination with 3 Tesla magnet
+∞
7.3
7
*
WX140
NOMESCO Finland
Parabulbar anesthesy
3.4
7.2
26
80
CA1CM
NOMESCO Finland
Eye and orbita extensive MRI examination with 3 Tesla magnet
30.5
7.2
9
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
6.2
7.1
18
30
ZXE20
NOMESCO Finland
More than three and less than five hours
2.1
6.9
67
341
104
Kela drug reimbursment
Thyroid insufficiency
2.6
6.7
39
158
Z3229
NOMESCO Finland
Other healthcare associate professional
2.4
6.6
46
203
ZXE00
NOMESCO Finland
One hour or less
1.7
6.6
183
1295
N03AX12
ATC
[U] gabapentin; oral
2.0
6.4
75
408
R4110
NOMESCO Finland
Physiotherapy
1.7
6.4
129
836
3504
FHL
Retroposition of two muscles
+∞
6.3
6
*
H50.59
ICD-10 Finland
Heterophor UNS
+∞
6.3
6
*
3780B
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Convergent concomitant strabismus[STRABISMUS CONVERGENS ALTERNANS]
+∞
6.3
6
*
CEC20
NOMESCO Finland
Recession and advancement of extraocular muscle
+∞
6.3
6
*
3780A
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Convergent concomitant strabismus[STRABISMUS CONCOMITANS CONVERGENS]
+∞
6.3
6
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
12.7
6.1
10
8
H52.2
ICD-10 Finland
Astigmatism
6.8
6.1
14
21
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
53
117
4.97
23.03
4.2
2.1
5.81
4.59
iu/l
0.26
31
51
180
1132
1.95
10.63
2.5
2.1
184.57
181.00
u/l
0.03
165
1079
233
1651
1.81
9.07
6.6
4.8
35.92
36.52
g/l
0.85
226
1573
261
1966
1.73
7.79
8.0
7.1
1.21
1.22
mmol/l
0.16
230
1730
237
1774
1.67
6.96
7.4
6.8
1.22
1.22
mmol/l
0.03
229
1655
17
45
3.88
5.86
1.1
1.0
—
—
—
0
0
220
1665
1.60
5.85
2.3
2.0
93.03
96.37
pmol/l
0.44
131
850
187
1365
1.61
5.76
4.0
3.0
2.35
2.36
mmol/l
0.69
176
1244
17
46
3.80
5.69
1.2
1.0
—
—
—
0
0
218
1663
1.57
5.50
15.1
11.1
1.19
1.19
inr
0.11
186
1357
15
29
5.31
5.43
1.1
1.0
—
—
—
0
0
52
263
2.10
5.42
5.2
3.5
4.35
4.62
pmol/l
1.20
52
233
191
1418
1.58
5.40
4.1
3.2
—
—
—
0
0
179
1318
1.57
5.20
4.1
3.2
116.48
98.27
e6/l
0.07
145
996
238
1869
1.55
5.18
3.2
2.6
72.89
75.66
nmol/l
0.84
223
1716
69
395
1.87
5.07
7.8
8.1
1.48
0.65
mmol/l
0.95
61
331
374
3271
1.67
5.00
6.3
4.4
14.81
14.63
pmol/l
0.72
363
3032
15
41
3.75
4.96
1.2
1.0
—
—
—
0
0
98
636
1.68
4.69
3.9
4.2
0.81
0.81
mmol/l
0.30
92
608
16
49
3.34
4.50
3.9
2.7
18.06
23.97
nmol/l
1.52
16
44
290
2420
1.51
4.49
13.1
9.9
3.95
3.97
e9/l
0.06
259
2116
13
28
4.74
4.40
1.4
1.2
0.68
0.53
ratio
—
5
15
25
101
2.56
4.37
2.0
2.5
7995.35
307.50
e6/l
0.51
17
80
10
16
6.36
4.31
2.3
1.4
—
—
—
0
0
125
883
1.56
4.21
2.9
2.6
5.69
7.41
e6/l
0.60
112
804
107
729
1.60
4.20
2.8
2.5
2.42
2.44
mmol/l
1.22
99
653
154
1141
1.52
4.17
3.9
3.2
0.29
0.37
e6/l
0.47
118
822
49
268
1.92
4.14
1.2
1.3
17.20
37.24
au/ml
—
5
18
52
291
1.88
4.10
1.4
2.8
70.07
69.37
ml/min/173m2
0.05
14
125
140
1021
1.53
4.07
2.7
3.6
1322.96
920.67
ng/l
0.32
121
868
24
99
2.50
4.03
2.0
2.4
21.73
14.05
e6/l
0.19
15
75
28
125
2.32
3.98
1.7
1.4
289.22
303.79
ug/g
0.11
15
78
438
4075
1.96
3.87
19.7
13.7
23.39
22.00
mg/l
0.37
360
3261
143
1058
1.50
3.86
3.0
2.4
2.79
2.94
mg/l
0.36
124
919
96
653
1.59
3.78
4.2
3.1
3.78
2.26
e6/l
0.52
54
318
48
270
1.87
3.74
1.6
1.5
26.48
21.48
iu/l
0.37
39
218
344
3027
1.49
3.71
9.6
7.5
82.80
80.69
u/l
0.29
332
2882
101
702
1.56
3.61
3.3
3.0
1.33
0.86
e6/l
0.57
61
363
275
2328
1.43
3.57
6.3
5.1
6.28
6.51
mmol/l
1.37
268
2187
51
298
1.80
3.53
2.3
2.4
40.85
18.51
au/ml
—
10
24
413
3800
1.67
3.48
7.4
5.3
1.84
1.86
mu/l
0.13
404
3572
59
363
1.71
3.42
3.0
2.9
0.21
0.22
g/l
0.34
54
344
9
18
5.07
3.38
1.7
1.1
—
—
—
0
0
160
1241
1.44
3.32
3.0
2.5
51.63
63.53
u/l
1.50
151
1159
9
20
4.57
3.12
4.0
4.4
0.89
1.50
ug/l
—
9
20
343
3058
1.44
3.11
5.0
4.2
10.46
10.46
mm/h
0.00
330
2862
103
743
1.49
3.08
1.6
1.6
429.34
28527571.13
pmol/l
0.76
93
645
21
93
2.32
3.08
2.0
1.6
—
—
—
0
0
244
2071
1.37
2.86
7.3
6.4
11.94
11.95
umol/l
0.00
232
1972
37
210
1.83
2.84
1.8
1.7
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
9
23
3.97
2.78
1.8
1.1
—
—
—
0
0
245
2094
1.35
2.69
4.3
3.1
118.97
98.80
ug/l
0.56
231
1979
257
2213
1.35
2.68
4.2
3.6
0.00
3.48
estimate
0.50
62
467
298
2630
1.36
2.62
5.8
4.3
1070.80
1373.84
e6/l
—
5
38
76
534
1.50
2.57
7.3
6.1
1.16
1.09
mmol/l
0.92
71
496
428
4032
1.62
2.57
21.8
15.9
3.94
3.96
mmol/l
0.73
421
3945
43
265
1.68
2.52
2.1
1.6
—
—
—
0
0
139
1097
1.38
2.51
1.7
1.6
20.11
21.13
nmol/l
0.37
126
941
77
546
1.49
2.50
1.8
1.6
1223.55
1215.99
nmol/l
0.02
63
415
9
26
3.51
2.49
2.0
1.9
—
—
—
0
0
8
21
3.86
2.47
2.0
1.2
—
—
—
0
0
220
1870
1.33
2.43
3.2
2.7
—
—
estimate
—
0
0
173
1425
1.34
2.35
3.2
3.2
44.75
30.41
u/l
0.83
166
1348
253
2203
1.32
2.32
4.2
3.5
0.00
0.00
estimate
0.50
59
465
53
353
1.56
2.30
7.3
9.5
1.18
1.36
mmol/l
0.94
53
347
13
53
2.49
2.29
1.3
1.2
—
—
—
0
0
86
636
1.43
2.25
2.9
2.3
12.83
13.34
umol/l
0.27
80
592
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
93
2.09
2.24
4.2
4.2
0.38
0.38
iu/ml
—
9
50
256
2242
1.31
2.21
4.3
3.6
0.00
0.01
estimate
0.50
61
433
163
1344
1.32
2.17
4.2
3.6
7.93
7.98
mmol/l
0.04
143
1161
93
707
1.39
2.08
3.6
3.7
43.75
314.46
ng/l
3.97
69
513
49
329
1.55
2.06
7.8
10.5
25.23
24.62
mmol/l
0.51
49
329
7
20
3.54
2.06
1.1
1.4
—
—
—
0
0
7
20
3.54
2.06
1.1
1.4
—
—
—
0
0
17
83
2.09
2.03
1.9
1.5
0.26
0.34
nmol/l
0.28
11
60
79
587
1.41
2.02
2.8
2.3
2.38
2.40
g/l
0.07
72
541
143
1174
1.31
1.94
4.4
3.6
0.00
0.00
estimate
0.80
60
440
386
3617
1.36
1.85
6.5
5.9
38.46
38.54
mmol/mol
0.06
373
3433
122
986
1.32
1.84
3.0
2.3
—
—
—
0
0
73
545
1.40
1.82
3.1
2.3
21.98
22.40
%
0.10
67
512
29
183
1.62
1.61
1.4
1.3
—
—
—
0
0
7
26
2.72
1.58
3.9
3.8
0.43
1.00
index
—
7
26
5
15
3.36
1.52
1.2
2.3
134.60
124.47
%
—
5
15
94
752
1.31
1.52
1.3
1.3
22.68
9.81
u/ml
0.30
34
294
118
976
1.28
1.48
3.9
3.4
1.02
1.02
kg/l
0.19
84
637
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
5
16
3.15
1.44
1.4
1.2
96.20
125.25
%
—
5
16
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
6
22
2.75
1.44
1.5
1.9
115.00
112.91
%
—
6
22
7
29
2.43
1.39
1.1
1.3
106.27
185.73
pmol/l
—
7
29
61
464
1.36
1.39
2.8
3.1
8.34
6.71
umol/l
0.39
50
405
303
2795
1.23
1.39
3.5
3.3
44.62
41.52
u/l
0.28
289
2673
22
135
1.66
1.38
1.8
1.4
0.00
0.07
iu/ml
—
6
23
5
17
2.96
1.36
1.0
1.4
—
—
—
0
0
5
17
2.96
1.36
1.0
1.4
—
—
—
0
0
14
75
1.89
1.35
1.4
1.3
10.96
3.27
ug/l
0.49
14
66
15
83
1.83
1.32
2.2
3.1
8.37
7.48
pmol/l
0.12
15
83
79
630
1.30
1.31
1.9
1.9
—
—
—
0
0
6
24
2.52
1.30
2.0
1.1
36.83
30.71
nmol/l
—
6
19
111
929
1.25
1.26
2.1
2.0
2.05
1.48
mg/l
0.25
79
719
61
473
1.33
1.24
1.8
1.8
—
—
—
0
0
391
3728
1.28
1.23
4.9
4.6
5.87
5.83
mmol/l
0.19
372
3465
457
4464
1.63
1.22
30.1
21.2
4.52
4.53
e12/l
0.20
452
4379
58
448
1.34
1.21
1.8
1.8
—
—
—
0
0
389
3710
1.27
1.20
18.8
13.1
86.32
86.33
ml/min/173m2
0.00
356
3383
8
38
2.12
1.19
1.1
1.1
—
—
—
0
0
13
72
1.83
1.16
1.3
1.2
5.14
3.50
u/ml
—
7
36
185
1651
1.20
1.12
4.4
3.4
0.00
0.02
estimate
0.96
51
387
26
177
1.50
1.10
2.0
1.9
5.82
5.63
iu/ml
—
8
40
136
1183
1.21
1.07
4.2
4.1
14.14
8.27
mg/mmol
0.32
89
744
13
74
1.78
1.07
1.4
1.2
—
—
—
0
0
13
74
1.78
1.07
1.4
1.2
—
—
—
0
0
13
74
1.78
1.07
1.1
1.3
—
—
—
0
0
9
47
1.93
1.02
7.6
1.9
10.22
10.55
mmol/l
—
9
47
50
389
1.32
1.02
2.5
2.3
31.69
30.74
u/l
0.05
45
324
17
107
1.61
1.01
4.2
2.9
2.50
1.71
index
0.33
12
58
7
36
1.96
0.97
3.9
3.5
17.86
13.58
index
—
7
26
49
386
1.30
0.93
6.0
6.4
—
—
—
0
0
6
28
2.16
0.92
1.3
2.8
111.50
92.75
%
—
6
28
435
4237
1.32
0.90
14.7
11.1
26.23
26.07
u/l
0.05
428
4137
156
1396
1.17
0.89
4.2
3.6
51.28
78.74
ng/l
0.22
104
913
402
3882
1.23
0.88
5.4
5.4
2.67
2.74
mmol/l
0.94
387
3651
6
30
2.01
0.87
2.8
1.6
—
—
—
0
0
18
120
1.52
0.86
1.1
1.2
—
—
—
0
0
378
3631
1.20
0.86
3.9
4.0
1.30
1.27
mmol/l
0.27
362
3395
398
3842
1.22
0.86
4.7
4.8
4.56
4.66
mmol/l
1.13
382
3629
134
1188
1.18
0.85
1.4
1.5
1.44
2.08
u/ml
0.40
39
316
38
294
1.32
0.83
3.9
3.8
1.25
1.23
mmol/l
1.60
33
258
36
462
0.76
0.82
4.3
4.4
28.48
32.05
%
1.82
29
316
12
73
1.66
0.82
1.4
1.2
9.00
2.43
u/ml
—
6
28
11
176
0.62
0.81
1.2
1.5
—
—
—
0
0
18
122
1.49
0.81
1.1
1.1
3.63
1.74
u/ml
—
10
73
109
954
1.19
0.81
2.4
2.9
324.37
332.94
umol/l
0.42
101
856
95
824
1.19
0.78
1.3
1.3
45.44
32.80
iu/ml
0.20
17
241
35
271
1.31
0.77
2.0
2.3
13.32
7.36
ug/l
0.40
30
246
11
173
0.63
0.76
1.2
1.1
0.94
0.90
g/l
0.15
11
173
6
34
1.77
0.76
1.2
1.3
—
—
—
0
0
0
28
0.00
0.76
0.0
5.5
—
37.60
—
0
5
9
53
1.71
0.76
1.1
1.1
89.22
96.71
%
—
9
48
13
196
0.65
0.75
3.7
3.2
1.02
1.02
ratio
0.27
13
187
17
116
1.48
0.75
1.7
2.8
—
—
—
0
0
23
167
1.40
0.75
2.0
1.6
7.54
9.50
u/l
0.36
15
124
7
39
1.81
0.72
2.0
1.1
—
—
—
0
0
11
170
0.64
0.72
1.1
1.1
1.50
1.55
g/l
0.23
11
170
7
40
1.76
0.71
2.0
1.2
—
—
—
0
0
5
27
1.86
0.68
3.6
2.5
—
—
—
0
0
14
94
1.50
0.67
2.0
3.9
1.11
2.06
ratio
—
9
54
18
128
1.42
0.66
1.3
1.1
—
—
—
0
0
53
443
1.22
0.65
4.9
5.9
6.28
5.74
kpa
1.96
53
433
18
129
1.41
0.64
1.3
1.1
—
—
—
0
0
24
182
1.34
0.62
3.5
1.5
—
—
—
0
0
8
49
1.64
0.62
1.0
1.0
—
—
—
0
0
44
363
1.23
0.61
4.4
3.1
—
—
—
0
0
17
122
1.41
0.61
1.7
1.3
—
—
—
0
0
0
23
0.00
0.58
0.0
1.6
—
—
—
0
0
6
35
1.72
0.58
1.7
1.1
112.67
111.89
pmol/l
—
6
35
19
141
1.36
0.57
1.1
1.2
0.66
3.37
u/ml
—
9
87
12
82
1.48
0.55
1.9
1.7
—
—
—
0
0
11
74
1.50
0.54
1.0
1.1
—
—
—
0
0
6
39
1.55
0.53
1.3
4.2
—
—
—
0
0
307
2955
1.11
0.49
3.4
3.4
—
—
—
0
0
7
47
1.50
0.47
1.0
1.2
357.86
366.60
pmol/l
—
7
42
41
347
1.20
0.47
1.4
1.3
217.14
151.63
u/ml
0.41
14
138
10
68
1.48
0.47
1.2
1.2
109.60
114.54
%
—
10
63
38
321
1.20
0.45
1.8
1.4
—
—
—
0
0
16
122
1.32
0.43
1.9
2.4
2.71
2.90
g/l
0.25
16
112
22
176
1.26
0.42
1.3
1.3
171.23
255.94
miu/ml
—
8
93
42
486
0.85
0.42
1.5
1.9
3.41
3.50
ratio
0.19
34
384
10
70
1.44
0.42
2.6
5.7
—
555.57
u/ml
—
0
7
10
70
1.44
0.42
1.1
1.4
—
—
—
0
0
5
33
1.52
0.41
4.8
4.0
—
—
—
0
0
0
16
0.00
0.41
0.0
2.2
—
—
—
0
0
10
138
0.72
0.41
1.2
1.5
—
—
—
0
0
19
151
1.27
0.39
1.5
1.3
—
—
—
0
0
9
67
1.35
0.38
1.0
1.3
—
—
—
0
0
8
111
0.72
0.37
2.4
1.8
—
—
—
0
0
14
180
0.77
0.37
2.1
1.6
—
—
—
0
0
8
115
0.69
0.37
2.3
2.5
13.64
11.27
mg/l
—
8
109
5
37
1.35
0.37
1.0
1.3
2.32
3.04
mg/l
—
5
37
390
3823
1.11
0.37
4.6
4.7
1.43
1.47
mmol/l
1.31
375
3589
5
77
0.65
0.36
1.4
1.8
—
—
—
0
0
13
99
1.32
0.36
2.1
2.5
0.00
0.05
g/l
0.49
13
91
6
43
1.40
0.35
1.0
1.1
—
—
—
0
0
6
44
1.37
0.34
1.0
1.1
—
—
—
0
0
6
44
1.37
0.34
1.0
1.1
—
—
—
0
0
6
45
1.34
0.34
1.0
1.1
—
—
—
0
0
6
87
0.69
0.33
1.8
1.5
—
—
—
0
0
7
52
1.35
0.31
1.7
1.4
—
—
—
0
0
7
52
1.35
0.31
1.7
1.4
—
—
—
0
0
7
53
1.33
0.31
1.7
1.4
—
—
—
0
0
131
1236
1.08
0.31
4.7
2.9
0.00
0.01
estimate
0.99
49
380
7
54
1.30
0.30
1.7
1.4
—
—
—
0
0
33
377
0.87
0.30
1.2
1.8
3.35
3.43
mmol/l
0.17
26
277
13
102
1.28
0.30
1.2
1.3
—
—
—
0
0
7
55
1.28
0.30
1.7
1.4
—
—
—
0
0
7
55
1.28
0.30
1.7
1.4
—
—
—
0
0
19
157
1.22
0.30
2.2
1.4
1.30
1.19
g/l
0.89
19
150
7
56
1.25
0.29
1.0
1.1
—
—
—
0
0
16
131
1.23
0.27
1.9
2.3
7.88
7.20
g/l
0.51
16
121
16
131
1.23
0.27
1.9
2.3
4.18
4.36
g/l
0.32
16
121
16
131
1.23
0.27
1.9
2.3
5.13
3.81
g/l
0.42
16
121
177
1697
1.07
0.27
1.8
1.9
1.28
1.34
mmol/l
0.49
150
1460
9
72
1.25
0.25
1.6
2.9
16.93
16.80
%
—
9
72
79
738
1.08
0.24
1.6
1.5
—
—
—
0
0
17
144
1.19
0.22
2.1
1.9
43.88
39.19
nmol/l
0.19
17
139
5
41
1.22
0.22
1.2
1.9
0.62
0.70
mmol/l
—
5
41
5
41
1.22
0.22
1.2
1.2
—
56.60
—
0
5
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
1.28
—
0
10
0
10
0.00
0.21
0.0
1.1
—
80.50
—
0
10
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
2.0
—
44.46
—
0
14
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
13
108
1.21
0.20
1.1
1.6
411.57
227.63
u/ml
—
7
53
38
346
1.11
0.20
3.6
4.5
480.03
7.00
ug/l
0.48
28
290
9
114
0.79
0.20
1.3
1.7
—
—
—
0
0
6
49
1.23
0.20
1.0
1.1
—
—
—
0
0
67
711
0.93
0.18
2.2
2.4
—
—
—
0
0
7
59
1.19
0.18
1.3
1.5
—
—
—
0
0
12
142
0.84
0.17
1.7
1.4
—
—
—
0
0
8
68
1.18
0.16
1.4
1.4
—
240.00
—
0
5
27
245
1.11
0.15
3.6
2.2
8573.70
4735.03
u/l
—
8
90
17
150
1.14
0.14
1.9
1.3
—
—
—
0
0
12
103
1.17
0.14
1.3
1.3
—
1.00
—
0
6
13
113
1.15
0.13
2.1
2.7
2.29
0.73
g/l
0.31
13
101
13
113
1.15
0.13
1.4
2.3
9.68
10.58
g/l
0.49
13
102
105
1086
0.96
0.12
1.8
1.8
—
—
—
0
0
24
262
0.91
0.12
1.4
1.3
—
—
—
0
0
14
123
1.14
0.12
1.8
1.7
—
—
—
0
0
70
670
1.05
0.12
5.1
4.4
21.81
22.12
%
0.06
33
288
51
534
0.95
0.10
1.6
1.8
1.40
1.42
%
0.14
46
484
5
44
1.14
0.10
1.0
1.1
—
—
—
0
0
15
135
1.11
0.10
2.0
1.9
—
—
—
0
0
14
155
0.90
0.09
1.9
1.5
—
—
—
0
0
11
97
1.14
0.09
1.5
2.5
0.00
0.00
g/l
-0.00
11
85
6
54
1.11
0.09
1.3
1.4
—
—
—
0
0
6
56
1.07
0.08
1.2
1.3
7.49
7.56
mmol/l
—
6
43
19
175
1.09
0.08
1.8
1.6
9.28
8.05
u/ml
—
5
43
64
662
0.96
0.08
2.1
2.3
—
—
—
0
0
32
303
1.06
0.08
6.7
4.8
0.95
1.57
mmol/l
0.50
25
214
6
70
0.86
0.07
1.2
1.1
—
—
—
0
0
8
92
0.87
0.07
1.1
1.3
—
—
—
0
0
8
94
0.85
0.06
1.1
1.3
—
—
—
0
0
9
100
0.90
0.06
1.1
1.3
—
—
—
0
0
10
110
0.91
0.05
1.5
1.6
—
—
—
0
0
10
109
0.92
0.04
2.3
1.9
169.90
229.05
pmol/l
—
10
103
21
200
1.05
0.04
1.3
1.5
0.28
0.27
mg/l
—
10
88
15
142
1.06
0.02
1.2
1.2
—
4.36
—
0
20
44
449
0.98
0.02
2.3
2.1
—
—
—
0
0
10
93
1.08
0.02
1.7
1.6
77.60
54.85
ug/l
—
10
93
20
193
1.04
0.01
7.6
5.4
9.49
9.00
kpa
0.53
20
187
11
104
1.06
0.01
1.4
1.5
—
—
—
0
0
10
95
1.05
0.00
1.1
2.0
—
—
—
0
0
12
123
0.97
0.00
1.8
1.7
—
—
—
0
0
37
375
0.99
0.00
2.2
1.9
—
—
—
0
0
30
296
1.01
0.00
6.9
6.7
24.72
23.97
mmol/l
0.55
30
296
51
507
1.01
0.00
3.2
3.0
0.60
0.72
ug/l
0.59
32
299
29
289
1.00
0.00
1.1
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
6.10
—
0
5
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
8
84
0.95
-0.00
1.0
1.1
—
2.27
—
0
19
0
9
0.00
-0.00
0.0
1.2
—
0.14
—
0
9
7
72
0.97
-0.00
1.6
1.5
—
—
—
0
0
6
66
0.91
-0.00
1.2
1.6
—
—
—
0
0
7
78
0.90
-0.00
5.1
3.6
18.29
27.87
u/ml
—
7
78
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_STRABNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_STRABNAS | 1.175 [0.87, 1.58] | 0.284 |
| Birth year | 0.994 [0.99, 1.0] | 0.171 |
During the follow-up period (1.1.1998 — 31.12.2019), 80 out of 1777 females with H7_STRABNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_STRABNAS | 1.232 [0.89, 1.7] | 0.202 |
| Birth year | 0.987 [0.98, 1.0] | 0.016 |
During the follow-up period (1.1.1998 — 31.12.2019), 75 out of 1539 males with H7_STRABNAS died.
Mortality risk
Mortality risk for people of age
years, who have H7_STRABNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.091% | 0.215% |
| 5 | 0.655% | 1.266% |
| 10 | 1.807% | 3.642% |
| 15 | 3.292% | 7.24% |
| 20 | 5.626% | 11.799% |
Relationships between endpoints
↥Index endpoint: H7_STRABNAS – Other specified and unspecified strabismus
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data